Indivior Pharmaceuticals, INC. (INDV) — SEC Filings

Overview

Indivior Pharmaceuticals, INC. (INDV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Mar 27, 2026: Indivior Pharmaceuticals, Inc. filed an Annual Report to Security Holders (ARS) on March 27, 2026, for the period ending December 31, 2025. The filing, with SEC Accession No. 0001104659-26-035513, provides a comprehensive overview of the company's performance and financial standing for the fiscal ye

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 4 bullish, 46 neutral. The dominant filing sentiment for Indivior Pharmaceuticals, INC. is neutral.

Filing Type Overview

Indivior Pharmaceuticals, INC. (INDV) has filed 1 ARS, 1 DEFA14A, 18 8-K, 3 10-Q, 3 8-K/A, 23 6-K, 1 10-K with the SEC between Dec 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Indivior Files 2025 Annual Report to Security Holders — ARS · Mar 27, 2026 Risk: low
  Indivior Pharmaceuticals, Inc. filed an Annual Report to Security Holders (ARS) on March 27, 2026, for the period ending December 31, 2025. The filing, with SEC
• Indivior Pharmaceuticals Files Definitive Proxy Materials — DEFA14A · Mar 27, 2026 Risk: low
  Indivior Pharmaceuticals, Inc. filed a DEFA14A on March 27, 2026, which includes additional definitive proxy soliciting materials. The filing, with SEC Accessio
• 8-K Filing — 8-K · Dec 22, 2025
• Indivior PLC Reports Executive and Director Changes — 8-K · Dec 18, 2025 Risk: medium
  On December 12, 2025, Indivior PLC filed an 8-K report detailing changes in its executive officers and board of directors. The filing indicates a departure of c
• 8-K Filing — 8-K · Dec 15, 2025
• Indivior PLC Terminates Material Definitive Agreement — 8-K · Nov 20, 2025 Risk: medium
  Indivior PLC announced on November 20, 2025, the termination of a material definitive agreement. The filing also includes Regulation FD disclosures and financia
• 8-K Filing — 8-K · Nov 14, 2025
• Indivior PLC Files 8-K on Financials and Operations — 8-K · Oct 30, 2025 Risk: low
  Indivior PLC filed an 8-K on October 30, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statement
• Indivior's Q3 Net Income Surges 91% on Strong SUBLOCADE Sales — 10-Q · Oct 30, 2025 Risk: medium
  Indivior PLC reported a significant increase in net income for the three months ended September 30, 2025, reaching $42 million, up from $22 million in the same
• Indivior PLC Files Amendment on Exit Costs — 8-K/A · Oct 30, 2025 Risk: medium
  Indivior PLC filed an amendment (8-K/A) on October 30, 2025, to a previous report dated August 26, 2025. This amendment pertains to costs associated with exit o
• Indivior PLC Files 8-K Current Report — 8-K · Oct 1, 2025 Risk: low
  Indivior PLC filed an 8-K on October 1, 2025, to report current information. The filing primarily serves as a notification of events and does not contain specif
• Indivior PLC Reports Exit/Disposal Costs — 8-K · Aug 26, 2025 Risk: medium
  On August 26, 2025, Indivior PLC filed an 8-K report detailing costs associated with exit or disposal activities. The filing does not specify the exact nature o
• Indivior Appoints New Chief Medical Officer — 8-K · Aug 22, 2025 Risk: low
  On August 20, 2025, Indivior PLC announced the appointment of Dr. Christian Angel as Chief Medical Officer, effective September 1, 2025. Dr. Angel will receive
• Indivior PLC Files 8-K/A Amendment on Officer/Director Changes — 8-K/A · Aug 4, 2025 Risk: medium
  Indivior PLC filed an amendment (8-K/A) on August 4, 2025, to a report originally dated June 20, 2025. The amendment pertains to the departure of directors or c
• Indivior PLC Files 8-K on Financials — 8-K · Jul 31, 2025 Risk: low
  On July 31, 2025, Indivior PLC filed an 8-K report detailing results of operations and financial condition, along with Regulation FD disclosures and financial s
• Indivior's Net Income Holds Steady at $278M in H1 2025 — 10-Q · Jul 31, 2025 Risk: low
  INDIVIOR PLC reported a significant increase in net income for the six months ended June 30, 2025, reaching $278 million, up from $278 million in the prior year
• Indivior PLC Files 8-K for June 30, 2025 — 8-K · Jun 30, 2025 Risk: low
  Indivior PLC filed an 8-K on June 30, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD disclosures and fina
• Indivior PLC Appoints New Chief Medical Officer — 8-K · Jun 24, 2025 Risk: medium
  Indivior PLC announced on June 20, 2025, the departure of its Chief Medical Officer, Dr. Robert L. Johnson, effective June 20, 2025. The company also announced
• Indivior PLC Files 8-K Report — 8-K · Jun 2, 2025 Risk: low
  On June 2, 2025, Indivior PLC filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific fin
• Indivior PLC Files 8-K: Other Events & Exhibits — 8-K · Jun 2, 2025 Risk: low
  Indivior PLC filed an 8-K on June 2, 2025, reporting events as of May 30, 2025. The filing is primarily for 'Other Events' and includes 'Financial Statements an
• Indivior PLC Files 8-K/A Amendment — 8-K/A · May 12, 2025 Risk: low
  Indivior PLC filed an amendment (8-K/A) on May 12, 2025, to a previous report dated May 8, 2025. This amendment pertains to the submission of matters to a vote
• Indivior PLC Files 8-K: Director Changes, Officer Appointments, Bylaw Amendments — 8-K · May 8, 2025 Risk: medium
  On May 8, 2025, Indivior PLC filed an 8-K report detailing several key events. These include the departure of directors or certain officers, the election of new
• Indivior PLC Files Q1 2025 10-Q — 10-Q · May 1, 2025 Risk: medium
  Indivior PLC filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025
• Indivior Acquires Opiant Pharmaceuticals for $145M — 8-K · Apr 24, 2025 Risk: medium
  Indivior PLC announced on April 24, 2025, that it has completed the acquisition of Opiant Pharmaceuticals, Inc. for an aggregate purchase price of approximately
• Indivior PLC Files 8-K Report — 8-K · Mar 27, 2025 Risk: low
  On March 27, 2025, Indivior PLC filed an 8-K report. The filing primarily serves as a notification of a Regulation FD Disclosure and the filing of Financial Sta
• Indivior PLC CFO Departs, Interim Appointed — 8-K · Mar 4, 2025 Risk: medium
  On March 2, 2025, Indivior PLC announced the departure of its Chief Financial Officer, Ryan Wm. Tomczyk, effective March 15, 2025. The company also announced th
• Indivior PLC Reports Total Voting Rights Update — 6-K · Mar 3, 2025 Risk: low
  Indivior PLC filed a Form 6-K on March 3, 2025, reporting its total voting rights. This filing is a routine update for foreign private issuers and includes an a
• 10-K Filing — 10-K · Mar 3, 2025
• Indivior PLC Files 6-K: Holdings Update — 6-K · Feb 28, 2025 Risk: low
  Indivior PLC filed a Form 6-K on February 28, 2025, reporting holdings in the company. This filing includes an announcement sent to the London Stock Exchange on
• Indivior PLC Appoints Joseph Ciaffoni as CEO — 6-K · Feb 27, 2025 Risk: low
  Indivior PLC announced on February 27, 2025, that Joseph Ciaffoni has been appointed as Chief Executive Officer. Ciaffoni previously served as Interim CEO and h
• Indivior PLC Files 6-K on Company Holdings — 6-K · Feb 25, 2025 Risk: low
  Indivior PLC filed a Form 6-K on February 25, 2025, reporting holdings in the company. The filing includes an announcement sent to the London Stock Exchange on
• Indivior PLC: FDA Approves Sublocade Label Changes — 6-K · Feb 24, 2025 Risk: low
  Indivior PLC announced on February 24, 2025, that the U.S. Food and Drug Administration (FDA) has approved label changes for its Sublocade product. This filing
• Indivior PLC Files 6-K for FY 2024 Results — 6-K · Feb 20, 2025 Risk: low
  Indivior PLC filed a Form 6-K on February 20, 2025, reporting its financial results for the period ending December 31, 2024. The filing includes unaudited conde
• Indivior PLC: FDA Approval Delay for SUBLOCADE Label Changes — 6-K · Feb 12, 2025 Risk: medium
  Indivior PLC announced on February 12, 2025, that the FDA approval for label changes to its SUBLOCADE product has been delayed. The company is working with the
• Indivior PLC Announces Share Transaction — 6-K · Feb 4, 2025 Risk: low
  On February 4, 2025, Indivior PLC announced a transaction in its own shares, as detailed in an announcement sent to the London Stock Exchange. The company is a
• Indivior PLC Appoints New Independent Non-Executive Director — 6-K · Feb 3, 2025 Risk: low
  Indivior PLC announced on February 3, 2025, the appointment of an Independent Non-Executive Director. This appointment is detailed in an announcement sent to th
• Indivior Buys Back $10M in Shares — 6-K · Jan 28, 2025 Risk: low
  Indivior PLC announced on January 28, 2025, that it has purchased 1,000,000 of its own ordinary shares at an average price of approximately $10.00 per share, to
• Indivior PLC Files 6-K on Company Holdings — 6-K · Jan 27, 2025 Risk: low
  On January 27, 2025, Indivior PLC filed a Form 6-K with the SEC, reporting holdings in the company. This filing includes an announcement sent to the London Stoc
• Indivior Buys Back Shares — 6-K · Jan 21, 2025 Risk: low
  Indivior PLC announced on January 21, 2025, that it has purchased 1,000,000 of its own ordinary shares at an average price of $1.75 per share, totaling approxim
• Indivior Buys Back 1M Shares for $10M — 6-K · Jan 14, 2025 Risk: low
  Indivior PLC announced on January 14, 2025, that it has purchased 1,000,000 of its own ordinary shares at an average price of approximately $10.00 per share. Th
• Indivior PLC Files 6-K with Historical US GAAP Financials — 6-K · Jan 10, 2025 Risk: low
  Indivior PLC filed a Form 6-K on January 10, 2025, to provide historical financial information in US GAAP. This filing includes an announcement sent to the Lond
• Indivior PLC Announces Share Transaction — 6-K · Jan 7, 2025 Risk: low
  On January 7, 2025, Indivior PLC announced a transaction involving its own shares, as detailed in an announcement sent to the London Stock Exchange. The company
• Indivior PLC Reports Total Voting Rights Update — 6-K · Jan 2, 2025 Risk: low
  Indivior PLC filed a Form 6-K on January 2, 2025, reporting its total voting rights. This filing is a routine update for foreign private issuers and includes an
• Indivior PLC Announces Share Transaction — 6-K · Dec 31, 2024 Risk: low
  On December 31, 2024, Indivior PLC announced a transaction involving its own shares, as detailed in an announcement sent to the London Stock Exchange. The compa
• Indivior Buys Back $10M in Shares — 6-K · Dec 26, 2024 Risk: low
  Indivior PLC announced on December 24, 2024, that it has purchased 1,000,000 of its own ordinary shares at an average price of approximately $10.00 per share, t
• Indivior PLC Files Director/PDMR Shareholding Report — 6-K · Dec 23, 2024 Risk: low
  On December 23, 2024, Indivior PLC filed a Form 6-K with the SEC, reporting director and PDMR shareholdings. The filing includes an announcement sent to the Lon
• Indivior PLC Files Form 6-K on Share Transactions — 6-K · Dec 17, 2024 Risk: low
  On December 17, 2024, Indivior PLC announced a transaction in its own shares. The company filed a Form 6-K with the SEC, reporting this activity. The filing is
• Indivior Buys Back Shares — 6-K · Dec 10, 2024 Risk: low
  Indivior PLC announced on December 10, 2024, that it repurchased 1,000,000 of its own ordinary shares at an average price of $1.95 per share, totaling approxima
• Indivior PLC Buys Back $17.25M in Shares — 6-K · Dec 3, 2024 Risk: low
  Indivior PLC announced on December 3, 2024, that it repurchased 1,000,000 of its own ordinary shares at an average price of $17.25 per share, totaling approxima
• Indivior PLC Reports Total Voting Rights Update — 6-K · Dec 2, 2024 Risk: low
  Indivior PLC announced on December 2, 2024, that as of November 30, 2024, its total issued share capital consisted of 1,118,180,000 ordinary shares of £0.10 eac

Risk Profile

Risk Assessment: Of INDV's 46 recent filings, 0 were flagged as high-risk, 12 as medium-risk, and 34 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Indivior Pharmaceuticals, INC.'s most recent 10-Q filing (Oct 30, 2025):

• Revenue: $314M
• Net Income: $42M
• EPS: $0.33
• Debt-to-Equity: N/A
• Cash Position: $445M
• Operating Margin: 13.7%
• Total Assets: $1,416M
• Total Debt: N/A

Key Executives

• Dr. Christian Angel
• Dr. Robert L. Johnson
• Dr. Ryan K. George
• Ryan Wm. Tomczyk
• Mark W. Smith
• Joseph Ciaffoni

Industry Context

The pharmaceutical industry, particularly in the addiction treatment sector, is characterized by high R&D costs, stringent regulatory oversight, and significant litigation risks. Companies like Indivior focus on specialized treatments, with key products like SUBLOCADE demonstrating strong market adoption. The competitive landscape involves both established pharmaceutical giants and smaller biotech firms vying for market share through innovation and strategic product lifecycle management.

Top Tags

disclosure (10) · sec-filing (8) · foreign-private-issuer (6) · share-buyback (6) · pharmaceuticals (4) · financials (4) · share-transaction (4) · insider-transaction (4) · management-change (3) · amendment (3)

Key Numbers

• ARS PDF Size: 3742975 — Size of the main ARS document file.
• Submission Text File Size: 5157157 — Size of the complete submission text file.
• SEC Accession Number: 0001104659-26-035500 — Unique identifier for the filing
• Filing Date: 2026-03-27 — Date the filing was accepted by the SEC
• Net income for Q3 2025: $42M — Increased from $22M in Q3 2024, a 90.9% rise
• Net income for nine months ended Sept 30, 2025: $108M — Swung from a net loss of $14M in the prior year
• Net revenue for Q3 2025: $314M — Up 2.3% from $307M in Q3 2024
• SUBLOCADE U.S. net revenue for Q3 2025: $203M — Increased from $177M in Q3 2024, a 14.7% rise
• Operating income for nine months ended Sept 30, 2025: $181M — Improved from an operating loss of $8M in the prior year
• Cash and cash equivalents as of Sept 30, 2025: $445M — Increased from $319M at Dec 31, 2024
• Total shareholders' deficit as of Sept 30, 2025: $207M — Improved from $337M at Dec 31, 2024
• Total accrued litigation settlement expenses: $406M — Comprising $106M current and $300M noncurrent as of Sept 30, 2025
• SEC File Number: 001-37835 — Identifies the company's filing history with the SEC.
• IRS Employer Identification No.: 98-1204773 — Tax identification number for the company.
• Annual Base Salary: $450,000 — For new Chief Medical Officer, Dr. Christian Angel.

Related Companies

INDI

Frequently Asked Questions